All In Biotech

Drug Trial Radar · NCT01442038

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization

Last checked: Nov 20, 2026Latest source record: Jul 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,651 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,651

Actual

Start

Oct 2011

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.

Conditions

  • Coronary Artery Disease
  • Angina Pectoris

Interventions

  • RanolazineDrug

    Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.

  • PlaceboDrug

    Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without RevascularizationTime frame: Baseline through end of study (average 90 weeks)

Locations

218 sites in 15 countries. Site status is shown where the registry gives one.

  • Cardiology, PC

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Heart Center Research, LLC

    Huntsville, Alabama

  • Scottsdale Healthcare

    Scottsdale, Arizona

  • Scottsdale Healthcare

    Scottsdale, Arizona

  • University of California San Diego

    La Jolla, California

  • Spectrum Clinical Research Institute, Inc

    Moreno Valley, California

  • Veterans Affairs San Diego Healthcare System

    San Diego, California

  • John Muir Medical Center Concord Campus

    Walnut Creek, California

  • South Denver Cardiology Associates, PC

    Littleton, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Cardiology Associates of Fairfield County, PC

    Stamford, Connecticut

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • Zasa Clinical Research

    Atlantis, Florida

  • Cardiology Research Associates

    Daytona Beach, Florida

  • Broward General Medical Center

    Fort Lauderdale, Florida

  • University of Florida

    Gainesville, Florida

  • Michigan Heart, PC

    Hialeah, Florida

  • Jacksonville Heart Center

    Jacksonville, Florida

  • University of Florida Health Sciences Center-Jacksonville

    Jacksonville, Florida

  • East Coast Institute for Research

    Jacksonville, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Florida Heart Institute

    Orlando, Florida

  • Cardiovascular Institute of Northwest Florida

    Panama City, Florida

  • Tallahassee Research Institute

    Tallahassee, Florida

  • Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute

    Tampa, Florida

  • University of Chicago Medical Center

    Chicago, Illinois

  • Gateway Cardiology, PC

    Jerseyville, Illinois

  • Indiana Heart Physicians, Inc.

    Indianapolis, Indiana

  • The Indiana Heart Hospital

    Indianapolis, Indiana

  • Northwest Indiana Cardiovascular Physicians

    Valparaiso, Indiana

  • Iowa Heart Center

    West de Moines, Iowa

  • Saint Joseph Cardiology Associates

    Lexington, Kentucky

  • Clinical Trials of America, Inc.

    Minden, Louisiana

  • Clinical Trials of America, Inc.

    Shreveport, Louisiana

  • Northeast Cardiology Associates

    Bangor, Maine

  • Baltimore Heart Associates

    Baltimore, Maryland

  • Union Memorial Hospital

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

Showing 40 of 218 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.